Category Archives: Psoriasis

I #39;m back
Hey guysss. So its been a while and my psoriasis is finally cleared for the most part so I wanted to make a vid for ya. Havnt really gained much, been maintaining and working out some but really all my body did was allow the weight to catch up with my body so I look huge anymore haha. But really just embracing my size and working extra hard on putting on some muscle. Buuut its difficult, and currently looking for a job and being broke, its hard or me to keep up and to even work out correctly, let alone eat properly, so I am asking if you wanted, it #39;d be a great help if you could donate a little to me, to help me grow and make my body a huge, sexy, muscle mass of awesomness. So message me of your interested. As always, sorry for the shit quality. So hope you enjoy, and thanks for all your support!From:GrowingCubsterViews:235 22ratingsTime:01:27More inPeople Blogs

Continued here:
I'm back - Video

JACKSON, Wis., Oct. 29, 2012 /PRNewswire/ --Lake Consumer Products, owner and manufacturer of the MG217 line of psoriasis treatment products, recently introduced an innovative new multi-symptom psoriasis treatment cream that's revolutionary in the psoriasis treatment category because it's fragrance-free, fast-absorbing and non-staining to skin and clothing.

(Photo: http://photos.prnewswire.com/prnh/20121029/CG01996)

"We really listened to our customers while developing this product," said Andy Wundrock, senior vice president of sales and marketing for Lake Consumer Products. "Our new MG217 Multi-Symptom Moisturizing Cream provides the moisture of an ointment with the fast-absorbing, non-drying characteristics of a gel. Combined with the fact that it truly is odorless and non-staining, our unique treatment cream allows psoriasis sufferers to use this product for daytime applications without worrying about staining their clothes or smelling like coal tar."

Lake Consumer Products also recently unveiled fresh new packaging for the line. After acquiring the MG217 brand from Triton Consumer Products last year, Lake Consumer felt the brand and the psoriasis treatment category in general was in need of product and packaging innovation. The updated look unlike anything else in the category features brighter colors and easy to understand product descriptions which are color-coded by active ingredient.

"Without changing the proven effective and trusted formulas of our existing items, the new MG217 packaging really makes these products current and relevant to today's consumer," said Wundrock. "Historically, psoriasis treatment products have had a very dark, heavy, medicinal look. We wanted to get away from that. Our packaging redesign not only presents our product assortment in a more attractive, contemporary and cohesive way, but it also makes it easier for consumers to understand what each product does and to quickly identify the active ingredient and which symptoms each product relieves so they can make a more informed decision."

For more information on the new MG217 Multi-Symptom Moisturizing Cream and new packaging of the line, visit http://www.mg217.com.

About Lake Consumer Products:

Lake Consumer Products Inc. markets and distributes numerous health and personal care products under several brands, including: Yeast-Gard, Yeast-Gard Advanced, vH Essentials, and MG217. For additional company or product details, please visit LakeConsumer.com.

Read this article:
Lake Consumer Products Announces Innovative New MG217® Psoriasis Treatment Cream that's Unlike Anything Else on the ...

Health Home>>>> Written by: Marilyn Linton, QMI Agency Oct. 29, 2012 Psoriasis. (Wikimedia Commons/HO) Common condition can be a 'soul crusher' for sufferers

There was a time when Newfoundlands Andrew Gosse would offer someone a pen and they wouldnt take it.

The St. Johns realtor, now 41, has suffered terribly with unsightly psoriasis since he was 17.

Lots of people think its contagious and it looks like it is, says Gosse who believes World Psoriasis Day, Monday, will bring some much-needed awareness to the skin condition that plagues between 2 to 4% of Canadians.

Gosse doesnt blame the people who rebuffed him years ago: If I didnt know much about this skin condition and met someone whose skin was scaly, I would feel awkward reaching out to them.

Psoriasis is a common chronic inflammatory skin condition that involves red elevated patches and flaking silvery scales. Normally, our skin cells replace themselves about every four weeks, but with psoriasis skin cells replace themselves in just days their accelerated growth forming thick scaly patches known as plaques.

Edmonton dermatologist Dr. Norman Wasel says its a skin condition that occurs due to overactivity of the immune system, but it is not a classic autoimmune disease. You can get it at any age.

Its not just a skin condition, says Dr. Wasel who is also director of Edmontons Stratica Medical. The accompanying inflammation can occur throughout the body, he explains; people with psoriasis have an increased risk of heart disease, arthritis, anxiety, diabetes, sleep apnea and a shorter life span in general.

Treatments can include everything from topical creams to light therapy, from oral medications aimed at regulating and normalizing skin cell turnover to those that suppress the immune response that causes inflammation.

Finding the right treatment requires patience and can be frustrating, says Dr. Wasel. A lot of people give up hope but there is no need for that today.

Go here to see the original:
Psoriasis isn't skin deep

NEW YORK (Reuters Health) - A new review of more than two dozen studies adds support to the link between the chronic skin disease psoriasis and diabetes.

In studies from the United States, Europe, the Middle East and elsewhere, participants with psoriasis had anywhere from an equal risk to an almost four-fold higher risk of developing diabetes than those without the skin condition.

According to the National Institutes of Health, more than three percent of adults in the U.S. have psoriasis, which is characterized by itchy, painful plaques on the skin.

Research has suggested psoriasis is tied to a higher chance of having heart disease or suffering a heart attack or stroke. One study of more than 500,000 people in the UK, released in June, also linked severe psoriasis with a 46 percent increased risk of diabetes (see Reuters Health story of June 19, 2012).

Still, people with psoriasis may not know about those risks and the importance of staying on top of their heart health, according to Dr. Jashin Wu, who has studied the link between psoriasis and other diseases at Kaiser Permanente Los Angeles Medical Center.

"They should get regular checks by their primary care doctor for high blood pressure, high cholesterol (and) diabetes - all those things are very important," Wu, who wasn't involved in the new analysis, told Reuters Health.

For the review, Dr. April Armstrong from the University of California, Davis and her colleagues combined the results of 27 past observational studies and found people with psoriasis were 59 percent more likely to have diabetes than "control" participants. In particular, those with severe psoriasis were almost twice as likely to also have the blood sugar disorder.

And among five studies that tracked diabetes-free people over time, those with psoriasis were 27 percent more likely to develop it than study participants without psoriasis, the researchers reported this week in the Archives of Dermatology.

Some researchers believe the chronic, body-wide inflammation behind psoriasis may also be responsible for increasing a person's risk of diabetes, as well as heart disease and stroke. But how exactly that works still isn't clear, Wu said.

In addition, people with psoriasis tend to be heavier, more depressed and less physically active, on average, than those without the condition, which could add to their underlying diabetes risk.

Read the original:
Analysis links psoriasis, diabetes

STOCKHOLM--(BUSINESSWIRE)-- World Psoriasis Day, October 29, 2012

Psoriasis is a serious, inflammatory, noncommunicable disease, associated with an increased risk of developing severe co-morbid conditions such as cardiovascular disease, diabetes and psoriatic arthritis, as well as depression and even suicidal ideation.[i] But yet there is a lack of recognition in many parts of the world for the seriousness, and severity, of psoriasis. In many countries, even getting the correct diagnosis can be a great difficulty. Dr Hoseah Waweru, Dermatologist and Vice President of IFPA states: In Kenya there are thirty dermatologists to a population of forty million. Most people with psoriasis will never see a dermatologist in their lives.

Psoriasis must be recognized as the serious disease it is. Psoriasis affects men and women of all countries and regions; it knows no borders. That is why it is imperative that the worlds leading health organization, WHO, recognizes psoriasis as the serious disease it is. Kathleen Gallant, Secretary of IFPA and Chair of IFPAs Task Force on NCDs, highlights the importance of this: All national health authorities need to be made aware of the physical, emotional and socioeconomic impacts of psoriasis, and include psoriasis in the public health agenda. By providing access to effective treatments, and by educating the medical professionals on how to correctly diagnose and treat psoriasis, a huge burden may be lifted both from the individuals suffering from the disease, as well as the society they live in.

Psoriasis is a global health challenge but there is hope. Psoriasis is a challenging disease, both to live with and to treat, but Lars Ettarp, President of IFPA, points out that there is hope for the future: Great advances have been made in the field of psoriasis, medically, scientifically and technologically. But now we have to ensure that these breakthroughs are made available to all people with psoriasis all over the globe.

About IFPA and World Psoriasis Day: IFPA, together with all its national member associations, is working to improve the quality of life for people suffering from psoriasis. Towards this end we are all united in a yearly World Psoriasis Day campaign, on October 29. In 2012 we are focusing on psoriasis as a global health challenge, and are asking all policy makers to put psoriasis on the agenda now, through a world-wide photo campaign. To read more about the campaign and view the photos, please visit http://www.worldpsoriasisday.com.

[i] Please see IFPAs report Psoriasis is a serious disease deserving global attention, available for download from http://www.ifpa-pso.org.

This information was brought to you by Cision http://www.cisionwire.com

Read this article:
International Federation of Psoriasis Associations: Put Psoriasis on the Agenda Now!

LONDON, October 29, 2012 /PRNewswire/ --

Psoriasis is a chronic inflammatory skin condition that affects more than 125 million people around the globe.[1],[2] People living with psoriasis experience flare-ups of sore and itchy skin,[1],[3] but the psychological effects of psoriasis can have an even greater impact on their everyday lives.[4]-[6]

(Logo: http://www.newscom.com/cgi-bin/prnh/20110606/460992 ) (Photo: http://photos.prnewswire.com/prnh/20121027/570724-b )

A recent survey conducted amongst 1,036 members of the UK general public, highlighted that psoriasis is understood to have a large psychological impact, with 82% agreeing that it could have huge impact on quality of life. However, nearly one third still mistook psoriasis for a contagious condition. Such common misconceptions and a lack of empathy can add greatly to the psychological burden of the disease.[7]

The Burden of Psoriasis patient research is one of the largest international studies to date investigating the impact that psoriasis has on people's lives. Patients involved in the qualitative stage of the study reported reactions of disgust and fear in response to their psoriasis, and their distress at having to cope with unnecessary comments, questions and staring.[8]

"There is still a huge lack of understanding about psoriasis in theUK," commented Dr Anthony Bewley, Whipps Cross University Hospital & Barts & the London NHS Trust, and Burden of Psoriasis patient research investigator. "We need to educate the general public about the psychological impact of the disease as they can play such an important role in helping to reduce the stigma associated with psoriasis."

Despite the recognition of the potential impact on quality of life, nearly 80% of people surveyed agreed that psoriasis is still a greatly misunderstood condition and 78% agreed that society has an important role to play in reducing stigma.

How does psoriasis impact on quality of life?

Further analyses of the findings from the quantitative stage of Burden of Psoriasis patient research were presented at the 21st EADV Congress in Prague, Czech Republic last month. The results showed that feelings of restriction, isolation, stigmatisation and anxiety are all associated with a high impact of psoriasis on patients' quality of life; and are actually more important than diagnosed symptom severity.[6]

Having learnt more about the everyday impact of psoriasis by reading a patient diary, over half of people questioned in the survey agreed that if they suffered from psoriasis they would likely feel depressed (56%) or anxious about meeting new people (58%).

Read more:
UK Survey Calls for Further Education to Help Eliminate Common Misconceptions About Psoriasis

LONDON--(BUSINESS WIRE)--

A new report,2 Recognising the life impact of psoriasis released today at a Parliamentary reception hosted by Paul Beresford MP, Chair of the All Parliamentary Group on Skin (Skin APPG), has unveiled an urgent need for multi-disciplinary care for people suffering with psoriasis. For the first time, the Psoriasis Association has collaborated with the Mental Health Foundation as part of the See Psoriasis: Look Deeper campaign. Along with other leading experts, the collaboration calls for the impact of psoriasis on a persons psychological wellbeing and overall quality of life, to be better recognised by politicians, the NHS and patients and their families. The See Psoriasis: Look Deeper initiative is funded by an educational grant from the global healthcare company Abbott.

Speaking to MPs from across the country, the collaboration together with patient groups and healthcare professionals, highlighted that the wider effects of psoriasis can go unrecognised by most. Psoriasis is estimated to effect up to 1.8 million people in the UK,3 the multi-faceted nature of psoriasis means the psychological impact of the condition can be just as debilitating as the physical symptoms. Approximately one third of psoriasis patients experience depression and anxiety,1 with 1 in 10 admitting to contemplating suicide.4 However, healthcare professionals tend to focus on the physical symptoms and often overlook asking patients about their psychological wellbeing.

Dr Christine Bundy, a member of the collaboration and Senior Lecturer in Behavioural Medicine at the University of Manchester says, There is often a cyclical link between the physical and psychological impact of psoriasis. The condition can cause emotional distress and worry for sufferers which can trigger a psoriasis flare and impact on progression of psoriasis, so patients can often feel trapped in a despairing cycle as they try to cope with their condition. We need to do more to ensure we are looking out for psychological symptoms and providing people with the condition the full support they need to manage psoriasis.

The Recognising the life impact of psoriasis report outlines calls to action for policy makers, emphasising an essential need for:

There is now more than ever, an opportunity to make a positive change for psoriasis patients via the NHS Commissioning Boards guidance to Clinical Commissioning Groups (CCGs), NICE clinical guidance and Quality Standards and CCG referral pathways. With the cost of mental health services currently reaching 6.6 billion (National survey of investment in Adult Mental Health Services)5 this is a figure that could be increased if psychological wellbeing of psoriasis patients is not addressed.

Andrew McCulloch, Chief Executive of the Mental Health Foundation adds: "The Mental Health Foundation has long called for the better integration of physical and mental health services. This includes routine assessment of the psychological needs of patients, in the light of the strong evidence of the inter-relationship and connection between physical health problems and mental health. It is essential that all staff supporting patients with a primary diagnosis of psoriasis are fully aware of the links between the two and are able to facilitate assessments and, where there is an assessed need, care and treatment that address all their health needs holistically".

The campaign also asks people with psoriasis to talk to their healthcare professional about the emotional impact psoriasis may be having on them, and to insist on help and support when needed.

Most people assume psoriasis just affects a person physically, however the affect is much deeper for patients that live with the condition day-to-day. All too often we hear from patients who are struggling with the emotional impact of psoriasis but do not feel able to ask their doctor for help. Some patients suggest that their GPs regard psoriasis as a minor complaint and do not consider the emotional aspects. We need doctors to treat people with psoriasis holistically, recognising the impact the condition can have on ones life, and we need patients to feel comfortable about proactively asking their doctors for help, knowing that they will be listened to says Helen McAteer from the Psoriasis Association.

To support the launch of the report and the See Psoriasis: Look Deeper campaign, patients were invited to submit a postcard addressed to their psoriasis to express how it impacts their daily lives and makes them feel. A creative display of the responses formed a central focus point at the launch event, demonstrating the support for the campaign and a need for change.

See the original post here:
Psoriasis Care Failing Patients

BEERSE, Belgium, October 29, 2012 /PRNewswire/ --

Pledge Your Support Today to Help Drive Much-needed Change for People With Psoriasis

Promising interim results from the Psoriasis Mandate have been released today to mark World Psoriasis Day. To date 1145 people across 40 European countries have pledged their support for five basic rights of people with psoriasis, but experts are urging people to keep signing the Mandate to drive much-needed improved standards of care.

To view the Multimedia News Release, please click: http://www.multivu.com/mnr/53825-world-psoriasis-day

Professor Matthias Augustin, University Medical Center of Hamburg, Germany, and Chair of the European Expert Working Group for Healthcare in Psoriasis (EEWGHP) says "Psoriasis affects approximately 14 million[1],[2],[3] people across Europe and there is significant variation in the standard of care people receive. Great steps are being made in the management of psoriasis, but lack of awareness and understanding of the condition by policy-makers and the general public adds to the distressing stigmatisation of this disease. The Psoriasis Mandate is our opportunity to give a voice to people living with psoriasis; to help them demand the high quality care that they deserve - please sign it."

The Psoriasis Mandate launched earlier this year by the EEWGHP, Janssen* and The European Umbrella Organisation for Psoriasis Movements (EUROPSO) to provide an opportunity for the community at large, people with psoriasis and their healthcare professionals to pledge their support for achieving the best care possible for those living with psoriasis. Anyone can sign the Psoriasis Mandate (http://www.psoriasis360.com/psoriasis-mandate) to show their support for five key rights of people with psoriasis:

To date, 18% of people who have signed the Psoriasis Mandate have psoriasis, 19% have family members or friends across Europe with psoriasis, 21% are healthcare professionals, and 42% of signatures are from members of the public who simply support the cause, demonstrating the growing support and understanding of the need to help people living with this debilitating condition.

The Psoriasis Mandate followed the publication of the first-ever Psoriasis White Paper in July 2012 by the EEWGHP,[4] whose principle aim is to improve clinical outcomes and quality of life for the 14 million people living with psoriasis in Europe.[1],[2],[3] The White Paper addresses the under-treatment of psoriasis in Europe and provides a framework for action. It calls on healthcare organisations, healthcare professionals, European regulatory bodies, governments, industry, academia and patient advocacy groups to act together implement change. The Psoriasis White Paper is available free of charge via a special feature page on the Journal of the European Academy of Dermatology and Venereology (JEADV) website (http://onlinelibrary.wiley.com/doi/10.1111/j.1468-3083.2012.04576.x/full).

Mr. Ottfrid Hillmann, President of EUROPSO, says "For too long now psoriasis has been a low priority. These days it is possible for people with psoriasis to live a normal life, but that can only be achieved through early access to high quality care. We continue to call on all people involved in the management of psoriasis, including healthcare professionals, people with psoriasis, their families, and governments, to pledge their support to improve care across Europe. We are all working towards a brighter future for those with psoriasis, but this will only be achieved with a unified approach."

About Psoriasis

See the original post:
Psoriasis Mandate Results Released to Mark World Psoriasis Day

10/17/2012 6:08 AM ET Psoriasis, a chronic inflammatory skin disease, is said to be probably one of the oldest known diseases. It is estimated that as many as 7.5 million Americans and 125 million people worldwide have psoriasis. Though there are several different types of psoriasis, the most prevalent form of the disease is plaque psoriasis.

The truth about psoriasis is that it is not just a cosmetic problem as this devastating disease causes physical pain as well as frustration and self-consciousness to the patients. There is no cure yet for psoriasis, but a number of treatments are available to manage its symptoms.

Working on the development of a treatment for patients with moderate to severe plaque psoriasis is Idera Pharmaceuticals Inc. (IDRA: Quote), a clinical stage biotechnology company.

For readers who are new to Idera, here's a brief overview of its pipeline and the upcoming events to watch out for...

The most-advanced compound in the company's pipeline is IMO-3100, which is under phase II testing in patients with moderate to severe plaque psoriasis. The phase II trial of IMO-3100 for psoriasis was initiated in April of this year and it completed the enrollment of 44 patients this month. Idera expects reporting top-line data from this phase II study by year-end 2012.

The clinical activity of IMO-3100, including the impact on Psoriasis Area Severity Index (PASI), mean focal psoriasis severity, and Physician Global Assessment (PGA) scores are being assessed in the phase II study. In addition, biopsies of psoriasis plaques are evaluated for treatment-related changes in epidermal thickness and immune cell infiltrates consistent with the intended mechanism of action, according to the company.

The completion of the phase II study for IMO-3100 in psoriasis is expected during the first half of 2013.

Amgen's Enbrel, Abbott Labs' Humira, and Johnson & Johnson's Remicade, Simponi and Stelara are some of the FDA-approved biologic drugs for psoriasis. The global psoriasis market is estimated to be worth around $4.5 billion to $5 billion.

Idera's psoriasis drug candidate - IMO-3100, is a dual antagonist of Toll-like receptor TLR7 and TLR9, which play a key role in inflammation and immunity.

Next in the company's pipeline is IMO-8400, a first-in-class antagonist of TLRs 7, 8, and 9, for the treatment of lupus. Given the fact that IMO-8400 has demonstrated preclinical efficacy - in mouse models of lupus, Idera anticipates initiating a phase I dose escalation trial during the fourth quarter of 2012 to evaluate the safety and pharmacodynamics of IMO-8400 in healthy subjects.

Follow this link:
Idera Pharma: Itching For Touch Up...

Editor's Choice Main Category: Eczema / Psoriasis Also Included In: Diabetes;Dermatology Article Date: 16 Oct 2012 - 13:00 PDT

Current ratings for: Psoriasis Patients Twice As Likely To Develop Diabetes

The study, led by UC Davis researchers, was published online in Archives of Dermatology, and found a strong association between the dry skin rash and blood sugar disorder.

Psoriasis is widespread skin condition that runs in families. It is characterized by red, raised, flaky and often itchy, rash, and is found mostly on the knees and elbows, but can appear anywhere. Doctors believe it is an autoimmune disease; the body thinks of the skin as foreign and therefore gives off an inflammatory response. Earlier studies have hinted that psoriasis could be a risk factor for diabetes.

April Armstrong, assistant professor of dermatology at UC Davis and lead investigator of this study, and her team examined 27 studies of patients with psoriasis. Five of these studies looked at how many of the patients developed diabetes during the period of study, 10 to 22 years. The remainder of the studies assessed the incidence of diabetes at the commencement of the study. In total, they examined over 314,000 people with psoriasis and compared them with 3.7 million people without the disease (a control group).

The collection of data for these studies shows that patients with mild psoriasis are more than 1.5 times more likely to develop diabetes than the general public, while those suffering from severe psoriasis are twice as likely.

Studies that assessed prevalence found patients with psoriasis had a 27 percent elevated risk of getting diabetes, compared with the general public.

All but one study found a link between psoriasis and diabetes. These trials contained data from outpatient clinics, insurance claims, and hospitals. The rate of diabetes was the same regardless of patients' ethnicities or countries. Armstrong explains:

She goes on to say:

More research can also verify other possible limiting factors that are seen in the current study; a factor that could be confusing, like concurrent medications used to treat psoriasis that may change the risk of developing diabetes.

Follow this link:
Psoriasis Patients Twice As Likely To Develop Diabetes